Search results
Compugen hits milestone with AstraZeneca cancer trial By Investing.com
Investing.com· 3 days agoThe trial is a crucial step in evaluating the drug as a first-line treatment for a specific type of...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 3 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock | The Motley Fool
The Motley Fool· 5 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (PFE -1.70%) and AstraZeneca (AZN...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 18 hours ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
Reuters via AOL· 5 days agoAmgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 24 hours agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? | The Motley Fool
The Motley Fool· 5 days agoAstraZeneca (AZN -0.70%) is embarking on a fresh business plan that will see it grow significantly...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 9 hours agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Lifted by Hsbc Holdings PLC
ETF DAILY NEWS· 4 days agoHsbc Holdings PLC raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the ...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Morningstar· 4 days agoGoldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral. Analysts led by Rajan Sharma said AstraZeneca
